FDA Oncology Announcements

Anti-CD22 ADC × Lymphoid × Clear all

2 Announcements

FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia

Drug: Besponsa (inotuzumab ozogamicin) · Anti-CD22 antibody-drug conjugate
Conditions: LymphoidOther hematologic neoplasm

FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL

Drug: BESPONSA (inotuzumab ozogamicin) · Anti-CD22 antibody-drug conjugate
Condition: Lymphoid